Botulinum toxin-A for the treatment of Raynaud syndrome

Archives of Dermatology

Volumn 148, Issue 4, 2012, Pages 426-428

  Smith, Lauren ^a   Polsky, David ^a   Franks, Andrew G ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; ISOSORBIDE; LIDOCAINE; TADALAFIL; VERAPAMIL;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEBRIDEMENT; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; DRUG WITHDRAWAL; FEMALE; HAND DISEASE; HAND SURGERY; HUMAN; MEDICAL HISTORY; MUSCLE WEAKNESS; ONYCHOLYSIS; PAIN; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SYMPATHECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; ULCER; ULCER HEALING;

EID: 84859956715     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.1144     Document Type: Article

References (8)

1. Bakst R, Merola JF, Franks AG Jr, Sanchez M. Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59(4):633-653.
2. Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010;35(12):2085-2092.
3. Neumeister MW, Chambers CB, Herron MS, et al. Botox therapy for ischemic digits. Plast Reconstr Surg. 2009;124(1):191-201.
4. Levien TL. Advances in the treatment of Raynaud's phenomenon. Vasc Health Risk Manag. 2010;6:167-177.
5. Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A. J Hand Surg Am. 2009; 34(3):446-452.
6. Bergstrom KG, Perelman RO. Treatment for Raynaud's: beyond calcium channel blockers. J Drugs Dermatol. 2008;7(5):497-500.
7. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized crossover trial. Rheumatology (Oxford). 2010;49(12):2420-2428.
8. Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Invest. 2004;34(4):312-313. (Pubitemid 38553602)